zoledronic acid has been researched along with lissamine rhodamine b in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
1 other study(ies) available for zoledronic acid and lissamine rhodamine b
| Article | Year |
|---|---|
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |